Sperimentazione in fase di reclutamento = ; Sperimentazione in corso = ; Sperimentazione conclusa = ; Finanziato da un ente associato a IRDiRC = ; Membro di una ERN =

Sperimentazioni cliniche nazionali

FRANCIA

ILE-DE-FRANCE
PARIS

AOA1 : Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 (Phase III)

Institut du Cerveau et de la Moelle épinière (ICM) - Hôpital Pitié-Salpêtrière

Institut du Cerveau et de la Moëlle épinière - INSERM U1127

Ulteriori dettagli

ITALIA

LAZIO
ROMA

Studio degli effetti del riluzolo su pazienti affetti da atassia cerebellare cronica

A.O. S. Andrea

U.O.C. di Neurologia

Ulteriori dettagli

AUSTRALIA

Victoria
ADDRESS: NOT PROVIDED - AU

NuPower Study: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) -AU

Institution: Information not provided - AU

Ulteriori dettagli

REGNO UNITO; GRAN BRETAGNA

Greater London
ADDRESS: NOT PROVIDED - GB

NuPower Study: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) -GB

Institution: Information not provided - GB

Ulteriori dettagli

Sperimentazioni cliniche internazionali

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

NuPower Study: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD).

Institution: Information not provided - US

Ulteriori dettagli